drugset
drugset / Trial / NCT04616339

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

NCT04616339 ↗

Phase 1 Completed 31 enrolled Pfizer
Non-randomizedCrossoverOpen-labelBasic science

Summary

The purpose of the study is to evaluate the effect of formulation on relative bioavailability of PF-06882961.

Timeline

Start
2020-11-04
Primary completion
2021-07-19
Completion
2021-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Danuglipron Small molecule 100 mg Oral

Indications

obesity disorder